BioLargo Protects its Intellectual Property, Revokes Pooph License Due to Failure to Pay and Other Contract Breaches
BioLargo (OTCQX:BLGO) has revoked Pooph Inc.'s technology license and terminated their agreement due to Pooph's failure to meet contractual obligations, including approximately $3.8 million in unpaid fees. The termination requires Pooph to immediately cease marketing and selling products incorporating BioLargo's patents and proprietary technology.
Prior to termination, Pooph had successfully leveraged BioLargo's technology to achieve over $50 million in annual sales and garnered thousands of positive customer reviews. BioLargo remains focused on advancing its technology portfolio in infection control, wound care, "forever chemicals" management, and innovative battery systems while protecting its intellectual property rights.
BioLargo (OTCQX:BLGO) ha revocato la licenza tecnologica a Pooph Inc. e ha risolto l'accordo a causa del mancato rispetto degli obblighi contrattuali da parte di Pooph, inclusi circa 3,8 milioni di dollari in tariffe non pagate. La risoluzione impone a Pooph di cessare immediatamente la commercializzazione e la vendita di prodotti che incorporano i brevetti e la tecnologia proprietaria di BioLargo.
Prima della risoluzione, Pooph aveva sfruttato con successo la tecnologia di BioLargo per raggiungere oltre 50 milioni di dollari di vendite annuali e aveva raccolto migliaia di recensioni positive da parte dei clienti. BioLargo rimane concentrata sull'avanzamento del proprio portafoglio tecnologico nei campi del controllo delle infezioni, della medicazione delle ferite, della gestione dei cosiddetti “forever chemicals” e di sistemi di batterie innovativi, tutelando al contempo i propri diritti di proprietà intellettuale.
BioLargo (OTCQX:BLGO) ha revocado la licencia tecnológica de Pooph Inc. y ha rescindido su acuerdo debido al incumplimiento de Pooph de sus obligaciones contractuales, incluyendo aproximadamente 3,8 millones de dólares en tarifas no pagadas. La terminación obliga a Pooph a cesar de inmediato la comercialización y venta de productos que incorporen las patentes y la tecnología propietaria de BioLargo.
Antes de la terminación, Pooph había aprovechado con éxito la tecnología de BioLargo para lograr más de 50 millones de dólares en ventas anuales y había obtenido miles de reseñas positivas de clientes. BioLargo continúa enfocándose en avanzar su portafolio tecnológico en control de infecciones, cuidado de heridas, gestión de los llamados “forever chemicals” y sistemas de baterías innovadores, mientras protege sus derechos de propiedad intelectual.
BioLargo (OTCQX:BLGO)가 Pooph Inc.의 기술 라이선스를 취소하고 계약을 해지했습니다. 이는 Pooph가 계약상의 의무를 이행하지 못했으며 미지급 수수료 약 380만 달러를 포함합니다. 해지 조치로 Pooph는 BioLargo의 특허 및 독점 기술을 포함하는 제품의 마케팅과 판매를 즉시 중단해야 합니다.
해지에 앞서 Pooph는 BioLargo의 기술을 성공적으로 활용해 연간 매출이 5천만 달러를 넘었고 수천 건의 긍정적 고객 리뷰를 얻었습니다. BioLargo는 감염 관리, 상처 치료, 이른바 ‘Forever Chemicals’ 관리, 혁신적인 배터리 시스템 등 자사의 기술 포트폴리오를 강화하는 데 집중하며 지적 재산권을 보호하고 있습니다.
BioLargo (OTCQX:BLGO) a révoqué la licence technologique de Pooph Inc. et résilié leur accord en raison du manquement de Pooph à ses obligations contractuelles, notamment environ 3,8 millions de dollars de frais impayés. La résiliation oblige Pooph à cesser immédiatement de commercialiser et de vendre des produits incorporant les brevets et la technologie propriétaire de BioLargo.
Avant la résiliation, Pooph avait exploité avec succès la technologie de BioLargo pour atteindre plus de 50 millions de dollars de ventes annuelles et avait recueilli des milliers d’avis positifs de clients. BioLargo demeure concentré sur l’avancement de son portefeuille technologique en contrôle des infections, soins des plaies, gestion des « forever chemicals » et systèmes de batteries innovants, tout en protégeant ses droits de propriété intellectuelle.
BioLargo (OTCQX:BLGO) hat Pooph Inc.s Technologielizenz widerrufen und ihre Vereinbarung gekündigt, weil Pooph seine vertraglichen Verpflichtungen nicht erfüllt hat, einschließlich rund 3,8 Millionen US-Dollar ausstehender Gebühren. Die Kündigung verpflichtet Pooph, unverzüglich mit der Vermarktung und dem Verkauf von Produkten, die Patente und proprietäre Technologien von BioLargo enthalten, aufzuhören.
Vor der Kündigung hatte Pooph erfolgreich BioLargos Technologie genutzt, um über 50 Millionen US-Dollar Jahresumsatz zu erzielen, und Tausende positiver Kundenbewertungen erhalten. BioLargo bleibt darauf fokussiert, sein Technologieportfolio in Infektionsschutz, Wundversorgung, dem Management sogenannter „Forever Chemicals“ und innovativen Batteriesystemen voranzutreiben, während es seine geistigen Eigentumsrechte schützt.
BioLargo (OTCQX:BLGO) قد أبطلت ترخيص Pooph Inc. التكنولوجي ونقضت اتفاقهما بسبب فشل Pooph في الوفاء بالتزاماته التعاقدية، بما في ذلك نحو 3.8 مليون دولار من الرسوم غير المدفوعة. الإنهاء يفرض على Pooph التوقف فوراً عن تسويق وبيع المنتجات التي تحتوي على براءات اختراع وتكنولوجيا BioLargo المملوكة.
قبل الإنهاء، استغلت Pooph بنجاح تقنية BioLargo لتحقيق أكثر من 50 مليون دولار من المبيعات السنوية وجمع آلاف التعليقات الإيجابية من العملاء. تظل BioLargo مركزة على تعزيز محفظة تقنياتها في مكافحة العدوى، رعاية الجروح، إدارة ما يُسمّى بـ“المواد الكيميائية الأبدية” وأنظمة البطاريات المبتكرة مع حماية حقوقها الملكية الفكرية.
BioLargo (OTCQX:BLGO) 已撤销 Pooph Inc. 的技术许可并终止了双方的协议，原因是 Pooph 未能履行合同义务，包括约 380万美元 的未付费用。终止协议要求 Pooph 立即停止营销和销售包含 BioLargo 专利和专有技术的产品。
在终止前，Pooph 已成功利用 BioLargo 的技术，实现了超过 5000万美元的年度销售额，并获得了数千条积极的客户评价。BioLargo 将继续专注于在感染控制、创伤护理、被称为“永久化学物质”的管理以及创新电池系统等领域推进其技术组合，同时保护其知识产权。
- Demonstrated market success with technology generating over $50 million in annual sales through Pooph
- Strong validation of BioLargo's odor-control technology in consumer market
- Company maintains diverse technology portfolio across multiple high-value sectors
- Loss of significant revenue stream from Pooph license agreement
- Outstanding unpaid fees of $3.8 million from Pooph
- Termination of major commercial partnership
Pooph owes BioLargo
WESTMINSTER, CA / ACCESS Newswire / September 25, 2025 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator that creates and commercializes sustainable technologies, today announced that it had revoked the technology license granted to Pooph Inc. ("Pooph") and was terminating the license agreement, after Pooph failed to meet its contractual obligations, including payments owed to BioLargo totaling approximately
Pooph's emergence as a nationally recognized consumer brand was made possible by BioLargo's products, technical and commercial know-how, extensive market experience, and the collaborative business relationship between the parties. Powered by BioLargo's proprietary technology, Pooph products reached more than
Looking Forward
BioLargo remains fully committed to advancing its broad portfolio of technologies, products, and services. Our commercial efforts continue to focus on delivering transformative solutions in infection control and wound care, breakthrough technologies for managing "forever chemicals," and innovative battery systems. We remain steadfast in protecting our intellectual property and expanding the reach of our proven odor-control technology into new markets-providing consumers with safe, effective, and environmentally friendly products.
"Our science has been validated in the marketplace at scale," said Dennis P. Calvert, CEO of BioLargo. "While we regret the outcome of this relationship, we remain confident in the strength of our technology and the significant opportunities ahead. Our duty is to our stockholders, our partners, and the integrity of our work-and we will continue to build on this proven success."
BioLargo filed a Form 8-K with the U.S. Securities and Exchange Commission on September 25, 2025 (https://www.biolargo.com/sec-filings).
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc.
View the original press release on ACCESS Newswire
FAQ
Why did BioLargo (BLGO) revoke Pooph's license agreement in 2025?
How much revenue did Pooph generate using BioLargo's technology?
What happens to Pooph products after BioLargo's license termination?
What are BioLargo's main business areas after the Pooph termination?
How much money does Pooph owe to BioLargo (BLGO)?
